Journal of Inherited Metabolic Disease

, Volume 36, Issue 3, pp 499–512

Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits

  • Guilherme Baldo
  • David F. Wozniak
  • Kevin K. Ohlemiller
  • Yanming Zhang
  • Roberto Giugliani
  • Katherine P. Ponder
Original Article


Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease due to α-L-iduronidase (IDUA) deficiency that results in the accumulation of glycosaminoglycans (GAG). Systemic gene therapy to MPS I mice can reduce lysosomal storage in the brain, but few data are available regarding the effect upon behavioral function. We investigated the effect of gene therapy with a long-terminal-repeat (LTR)-intact retroviral vector or a self-inactivating (SIN) vector on behavioral function in MPS I mice. The LTR vector was injected intravenously to 6-week-old MPS I mice, and the SIN vector was given to neonatal or 6-week-old mice. Adult-LTR, neonatal-SIN, and adult-SIN-treated mice achieved serum IDUA activity of 235 ± 20 (84-fold normal), 127 ± 10, and 71 ± 7 U/ml, respectively. All groups had reduction in histochemical evidence of lysosomal storage in the brain, with the adult-LTR group showing the best response, while adult-LTR mice had reductions in lysosomal storage in the cristae of the vestibular system. Behavioral evaluation was performed at 8 months. Untreated MPS I mice had a markedly reduced ability to hold onto an inverted screen or climb down a pole. LTR-vector-treated mice had marked improvements on both of these tests, whereas neonatal-SIN mice showed improvement in the pole test. We conclude that both vectors can reduce brain disease in MPS I mice, with the LTR vector achieving higher serum IDUA levels and better correction. Vestibular abnormalities may contribute to mobility problems in patients with MPS I, and gene therapy may reduce symptoms.

Supplementary material

10545_2012_9530_MOESM1_ESM.pdf (2.2 mb)
ESM 1(PDF 2,303 kb)


  1. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. Biol Blood Marrow Transplant 14:485–498PubMedCrossRefGoogle Scholar
  2. Aronovich EL, Bell JB, Khan SA et al (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 17:1136–1144PubMedCrossRefGoogle Scholar
  3. Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRefGoogle Scholar
  4. Baldo G, Wu S, Howe R et al (2011) Pathogenesis of aortic dilatation in MPS VII mice may involve complement activation. Mol Genet Metab 104:608–619PubMedCrossRefGoogle Scholar
  5. Banks WA (2004) Are the extracellular pathways a conduit for the delivery of therapeutics to the brain. Curr Pharm Des 10:1365–1370PubMedCrossRefGoogle Scholar
  6. Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP (2007) Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90:181–192PubMedCrossRefGoogle Scholar
  7. Ciron C, Desmaris N, Colle MA et al (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60:204–213PubMedCrossRefGoogle Scholar
  8. Di Domenico C, Di Napoli D, Gonzalez Y et al (2006) Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17:1112–1121PubMedCrossRefGoogle Scholar
  9. Ellinwood NM, Ausseil J, Desmaris N et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251–259PubMedCrossRefGoogle Scholar
  10. Fuller GN, Burger PC (2007) Central nervous system. In: Mills S (ed) Histology for Pathologists, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 273–319Google Scholar
  11. Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR (2011) Blood-brain barrier impairment in an animal model of MPS III B. PLoS One 6:e16601PubMedCrossRefGoogle Scholar
  12. Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 105:2616–2621PubMedCrossRefGoogle Scholar
  13. Hartung SD, Frandsen JL, Pan D et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9:866–875PubMedCrossRefGoogle Scholar
  14. Heldermon CD, Hennig AK, Ohlemiller KK et al (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2:e772PubMedCrossRefGoogle Scholar
  15. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182–188PubMedCrossRefGoogle Scholar
  16. Kobayashi H, Carbonaro D, Pepper K et al (2005) neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11:776–789PubMedCrossRefGoogle Scholar
  17. Liu Y, Xu L, Hennig AK et al (2005) Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11:35–47PubMedCrossRefGoogle Scholar
  18. Ma X, Liu Y, Tittiger M et al (2007) Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 15:889–902PubMedGoogle Scholar
  19. Metcalf J, Ma X, Linders B, Wu S et al (2010) A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 18:334–342PubMedCrossRefGoogle Scholar
  20. Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and Molecular Basis of Inherited Disease. McGraw Hill, New York, pp 3421–3452Google Scholar
  21. Ohlemiller KK, Hennig AK, Lett JM, Heidbreder AF, Sands MS (2002) Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 16:969–984Google Scholar
  22. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100:1902–1907PubMedCrossRefGoogle Scholar
  23. Osborne MJ, McElmurry RT, Lees CJ et al (2011) Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19:450–460CrossRefGoogle Scholar
  24. Pan D, Sciascia A, Vorhees C, Williams MT (2008) Progression of multiple behavior deficits with various age of onsets in a murine model of Hurler syndrome. Brain Res 1188:241–253PubMedCrossRefGoogle Scholar
  25. Ponder KP, Haskins ME (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7:1333–1345PubMedCrossRefGoogle Scholar
  26. Reolon GK, Braga LM, Camassola M et al (2006) Long-term memory for aversive training is impaired in IDUA-/- mice, a genetic model of mucopolysaccharidosis type I. Brain Res 1076:225–230PubMedCrossRefGoogle Scholar
  27. Reolon GK, Reinke A, de Oliveira MR et al (2009) Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cell Mol Neurobiol 29:443–448PubMedCrossRefGoogle Scholar
  28. Schachern PA, Cureoglu S, Tsuprun V, Paparella MM, Whitley CB (2007) Age-related functional and histopathological changes of the ear in the MPS I mouse. Int J Pediatr Otorhinolaryngol 71:197–203PubMedCrossRefGoogle Scholar
  29. Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 350:1960–1969PubMedCrossRefGoogle Scholar
  30. Thomas JA, Beck M, Clarke JT, Cox GF (2010) Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 33:421–427PubMedCrossRefGoogle Scholar
  31. Trobridge GD (2011) Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 11:581–593PubMedCrossRefGoogle Scholar
  32. Visigalli I, Delai S, Politi LS et al (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116:5130–5139PubMedCrossRefGoogle Scholar
  33. Vogler C, Levy B, Grubb JH et al (2005) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102:14777–14782PubMedCrossRefGoogle Scholar
  34. Walkley SU (2004) Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15:433–444PubMedCrossRefGoogle Scholar
  35. Wang D, Zhang W, Kalfa TA et al (2009a) Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci USA 106:19958–19963PubMedGoogle Scholar
  36. Wang RY, Cambray-Forker EJ, Ohanian K et al (2009b) Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab 98:406–411PubMedCrossRefGoogle Scholar
  37. Watson G, Bastacky J, Belichenko P et al (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 13:917–925PubMedGoogle Scholar
  38. Wolf DA, Lenander AW, Nan Z et al (2011) Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 43:123–133PubMedCrossRefGoogle Scholar
  39. Wozniak DF, Hartman RE, Boyle MP et al (2004) Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis 17:403–414PubMedCrossRefGoogle Scholar
  40. Wozniak DF, Xiao M, Xu L, Yamada KA, Ornitz DM (2007) Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14. Neurobiol Dis 26:4–26CrossRefGoogle Scholar
  41. Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120:e37–e46PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  • Guilherme Baldo
    • 1
    • 5
  • David F. Wozniak
    • 2
  • Kevin K. Ohlemiller
    • 3
  • Yanming Zhang
    • 1
  • Roberto Giugliani
    • 5
  • Katherine P. Ponder
    • 1
    • 4
  1. 1.Department of Internal MedicineWashington University School of MedicineSt. LouisUSA
  2. 2.Department of PsychiatryWashington University School of MedicineSt. LouisUSA
  3. 3.Department of OtolaryngologyWashington University School of MedicineSt. LouisUSA
  4. 4.Department of Biochemistry and Molecular BiophysicsWashington University School of MedicineSt. LouisUSA
  5. 5.Gene Therapy CenterHospital de Clinicas de Porto AlegrePorto AlegreBrazil

Personalised recommendations